Considerations for the prediction of survival time in pancreatic cancer based on registry data

被引:1
|
作者
Bajaj, Gaurav [1 ]
Dombrowsky, Erin [1 ]
Yu, Qilu [2 ]
Agarwal, Banke [3 ]
Barrett, Jeffrey S. [1 ]
机构
[1] Childrens Hosp Philadelphia, Lab Appl PK PD, Dept Clin Pharmacol & Therapeut, Philadelphia, PA 19104 USA
[2] Westat Corp, Rockville, MD USA
[3] St Louis Univ, Dept Gastroenterol, St Louis, MO 63103 USA
关键词
Pancreatic cancer; SEER; Survival prediction; Registry data; DOSE RATE GEMCITABINE; TUMOR SIZE; PHASE-II; ADENOCARCINOMA; COMBINATION; CISPLATIN; ONCOLOGY; DESIGN; MODELS; STILL;
D O I
10.1007/s10928-013-9327-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Semi-parametric and parametric survival models in patients with pancreatic adenocarcinoma (PC) using data from Surveillance, Epidemiology, and End Result (SEER) registry were developed to identify relevant covariates affecting survival, verify against external patient data and predict disease outcome. Data from 82,251 patients was extracted using site and histology codes for PC in the SEER database and refined based on specific cause of death. Predictors affecting survival were selected from SEER database; the analysis dataset included 2,437 patients. Survival models were developed using both semi-parametric and parametric approaches, evaluated using Cox-Snell and deviance residuals, and predictions were assessed using an external dataset from Saint Louis University (SLU). Prediction error curves (PECs) were used to evaluate prediction performance of these models compared to Kaplan-Meier response. Median overall survival time of patients from SEER data was 5 months. Our analysis shows that the PC data from SEER was best fitted by both semi-parametric and the parametric model with log-logistic distribution. Predictors that influence survival included disease stage, grade, histology, tumor size, radiation, chemotherapy, surgery, and lymph node status. Survival time predictions from the SLU dataset were comparable and PECs show that both semi-parametric and parametric models exhibit similar predictive performance. PC survival models constructed from registry data can provide a means to classify patients into risk-based subgroups, to predict disease outcome and aide in the design of future prospective randomized trials. These models can evolve to incorporate predictive biomarker and pharmacogenetic correlates once adequate causal data is established.
引用
收藏
页码:527 / 536
页数:10
相关论文
共 50 条
  • [41] A transcriptomic signature for survival prediction in patients with resectable pancreatic cancer
    Nakamura, Kota
    Nishiwada, Satoshi
    Yasuda, Satoshi
    Nagai, Minako
    Matsuo, Yasuko
    Kohara, Yuichiro
    Doi, Shunsuke
    Sakata, Takeshi
    Kodera, Yasuhiro
    Ajay, Goel
    Sho, Masayuki
    CANCER SCIENCE, 2025, 116 : 634 - 634
  • [42] Pancreatic cancer survival prediction via inflammatory serum markers
    Mira Lanki
    Hanna Seppänen
    Harri Mustonen
    Aino Salmiheimo
    Ulf-Håkan Stenman
    Marko Salmi
    Sirpa Jalkanen
    Caj Haglund
    Cancer Immunology, Immunotherapy, 2022, 71 : 2287 - 2292
  • [43] Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment
    Matsubara, Junichi
    Ono, Masaya
    Honda, Kazufumi
    Negishi, Ayako
    Ueno, Hideki
    Okusaka, Takuji
    Furuse, Junji
    Furuta, Koh
    Sugiyama, Emiko
    Saito, Yoshiro
    Kaniwa, Nahoko
    Sawada, Junichi
    Shoji, Ayako
    Sakuma, Tomohiro
    Chiba, Tsutomu
    Saijo, Nagahiro
    Hirohashi, Setsuo
    Yamada, Tesshi
    MOLECULAR & CELLULAR PROTEOMICS, 2010, 9 (04) : 695 - 704
  • [44] Individualized Prediction of Breast Cancer Survival Using Flexible Parametric Survival Modeling: Analysis of a Hospital-Based National Clinical Cancer Registry
    Pongnikorn, Donsuk
    Phinyo, Phichayut
    Patumanond, Jayanton
    Daoprasert, Karnchana
    Phothong, Pachaya
    Siribumrungwong, Boonying
    CANCERS, 2021, 13 (07)
  • [45] Time-range based sequential mining for survival prediction in prostate cancer
    Kaur, Ishleen
    Doja, M. N.
    Ahmad, Tanvir
    JOURNAL OF BIOMEDICAL INFORMATICS, 2020, 110
  • [46] Radiomics-Based Survival and Recurrence Prediction for Pancreatic Cancer Following Stereotactic Body Radiotherapy
    Parr, E.
    Du, Q.
    Zhang, C.
    Lin, C.
    Kamal, A.
    McAlister, J.
    Liang, X.
    Bavitz, K.
    Rux, G.
    Hollingsworth, M. A.
    Baine, M.
    Zheng, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E284 - E284
  • [47] SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
    van den Boom, Hector G.
    Abu-Hanna, Ameen
    ter Veer, Emil
    van Kleef, Jessy Joy
    Lordick, Florian
    Stahl, Michael
    Ajani, Jaffer A.
    Guimbaud, Rosine
    Park, Se Hoon
    Dutton, Susan J.
    Bang, Yung-Jue
    Boku, Narikazu
    Mohammad, Nadia Haj
    Sprangers, Mirjam A. G.
    Verhoeven, Rob H. A.
    Zwinderman, Aeilko H.
    van Oijen, Martijn G. H.
    van Laarhoven, Hanneke W. M.
    CANCERS, 2019, 11 (02):
  • [48] Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model
    Anouk E. J. Latenstein
    Stijn van Roessel
    Lydia G. M. van der Geest
    Bert A. Bonsing
    Cornelis H. C. Dejong
    Bas Groot Koerkamp
    Ignace H. J. T. de Hingh
    Marjolein Y. V. Homs
    Joost M. Klaase
    Valery Lemmens
    I. Quintus Molenaar
    Ewout W. Steyerberg
    Martijn W. J. Stommel
    Olivier R. Busch
    Casper H. J. van Eijck
    Hanneke W. M. van Laarhoven
    Johanna W. Wilmink
    Marc G. Besselink
    Annals of Surgical Oncology, 2020, 27 : 2516 - 2524
  • [49] A proposed model for prediction of survival based on a follow-up study in unresectable pancreatic cancer
    Forssell, Henrik
    Wester, Michael
    Akesson, Katrin
    Johansson, Sigrid
    BMJ OPEN, 2013, 3 (12):
  • [50] Risk factors and survival prediction of pancreatic cancer with lung metastases: A population-based study
    Yao, Zong-Xi
    Tu, Jun-Hao
    Zhou, Bin
    Huang, Yang
    Liu, Yu-Lin
    Xue, Xiao-Feng
    FRONTIERS IN ONCOLOGY, 2022, 12